Daniel Han Pursues His Passion for Health Care Management With a Master of Health Administration (MHA) Degree

Jul 13, 2023 | School

After entering the MHA program at Mount Sinai’s Graduate School of Biomedical Sciences in 2021, Daniel Han accepted a position as Assistant Project Manager in the Department of Dermatology Clinical Trials Office at the Mount Sinai Doctors faculty practice, where he continues to work after completing the program in 2023.

In the following Q&A, Mr. Han discusses how he expects his degree to lay the foundation for a career in health administration.

Can you describe your current job?

I am responsible for coordinating and managing various aspects of clinical research projects in our department. This includes protocol development, regulatory compliance, patient recruitment, and coordination with the leadership teams. This job has given me valuable experience in project management and data analysis, and it has allowed me to collaborate with colleagues throughout the Mount Sinai Health System.

What first attracted you to this field of study?

I am passionate about health care management, and I want to develop a deeper understanding of how the health care sector operates and acquire the specialized skills, including leadership skills, to enable me to address the challenges and emerging trends in the industry. I want to make a difference, not only in the lives of patients, but also in the efficiency, cost-effectiveness, and quality of patient care achieved in hospitals and health care systems.

How, specifically, does this program prepare students for a career in health care management?

This program emphasizes a multidisciplinary approach to health care administration and offers a wide range of courses including finance, management, policy, and information technology. The health informatics and technology courses have sparked my interest in finding opportunities to improve the efficiency and accuracy of electronic health record data mining for patient recruitment in clinical trials. One of the things I appreciated most was the opportunity to gain insight from the executive leaders at Mount Sinai who are experts in their fields. I believe that the skills and knowledge I have gained through this program’s curriculum will not only benefit me in my current project manager role but also help me achieve my long-term career goals in health care administration.

One of the things I find appealing about Mount Sinai is the institution’s overall commitment to advancing patient care and driving medical advances, which aligns with my own goals. Mount Sinai fosters a collaborative environment that encourages an exchange of ideas and promotes a holistic approach to health care. And I believe in their commitment to diversity, equity, and inclusion.

What’s next?

I see myself using the tools that I learned—and practiced—during my graduate studies to help me gain a leadership position within a health care organization, preferably at Mount Sinai. I have had the opportunity to learn from senior- and executive-level professionals already established in their fields, and I plan to build on that strong foundation to advance to high-level managerial or executive positions, which is my career goal. Ultimately, I want to make a meaningful impact on patient outcomes and the overall delivery of health care services.

Adina Singh Earned a Master of Public Health (MPH) Degree as a First Step Toward Addressing Health Care Disparities in Her Community

Jul 13, 2023 | School

As a first-generation American born to South Asian immigrants in a working-class neighborhood in Queens, New York, Adina Singh knew that many in her community were in poor health. It wasn’t until her sophomore year at Hunter College that she realized that many immigrants, especially older people, do not have the same access to health care as others. That’s when she knew she wanted to work toward a solution, which led her to pursue an MPH in Health Care Management at Mount Sinai’s Graduate School of Biomedical Sciences.

In the following Q&A, Ms. Singh discusses how her experience at Icahn Mount Sinai prepared her for addressing health care gaps among New Yorkers.

Why an MPH degree?

Living in an immigrant community, I see the health struggles this population goes through, especially our parents and grandparents. They don’t know how to access health care and have not been educated on the importance of going to their doctor’s visits, following up, and doing the things necessary to stay healthy. As a result, they may develop chronic illnesses like diabetes, which affect their quality of life and can become life-threatening. Once I realized the health disparities among New Yorkers, particularly for minorities and immigrants, I knew I wanted to be part of the solution. That’s why I chose public health. By focusing specifically on health care management, I will be able to initiate and implement programs that people can access and also learn how to practice self-advocacy confidently when seeking care.

What were your top achievements as a master’s student?

For my applied practice experience fieldwork, I focused on addressing food insecurity in the neighborhoods surrounding Mount Sinai, including Harlem. I worked with Mount Sinai’s KidsThrive program, which predominantly serves children on public insurance and screens for food insecurity, offers emergency food packages from our onsite food pantry to families in need, and refers them to community-based organizations at the Mount Sinai Pediatric Associates clinic. After seeing their pediatrician, families can go down the hall to the food pantry for an emergency food package. It helps sustain them while we refer them to a long-term program through New York Common Pantry [New York City’s largest community-based food pantry that focuses on underserved communities] for food-related services. There, they receive food packages on a regular basis, among other food-related services.

Through KidsThrive, we went beyond sustenance to focus on the quality of the food packages and their appropriateness for each family. We created recipes that suited each family’s needs, taking into account preparation time, new cuisines they were interested in trying, and more. Additionally, we created a value-based payment proposal for a Medicaid insurance plan that would identify how to measure and track the impact of food insecurity interventions in our pediatric clinic population.

What are the strong points of this master’s program?

Mount Sinai is amazing and what stands out for me is the phenomenal faculty. They’re all busy in the field of public health—as doctors or program coordinators, even as the president of a hospital—and yet they all contribute to the work that students are doing and support us so that we, too, can contribute one day.

They are very approachable. If a student asks for input on a project or career advice, faculty will help. They support you as a person and as a young professional. Our faculty and administration are role models and show us that there are folks who want to leave our community better than they found it. They truly care about their students, even after they graduate. Some graduates come back as course instructors or program managers, and I think that speaks volumes, that folks want to come back to Mount Sinai, which has given them so much.

What’s next?

I want to contribute to the work that’s already being done in New York to promote health literacy and self-management of chronic health diseases within minority populations in New York City. Eventually, I want to add clinical understanding and advocacy to my toolbox by becoming a physician to bridge this gap. I want to look at my patients holistically and not just treat their symptoms, but also look for the root causes. If a child has asthma, you can give them an inhaler. But if there’s mold in the house, or leaking pipes that cause the paint to chip in the walls, you can give them that inhaler, but the root of the problem is not solved. I want to be part of a team that will address these issues.

“We Treated Patients With Elite Nursing Care”: 106-Year-Old Alum Recalls Training She Received at Beth Israel School of Nursing

Updated on Jul 14, 2023 | Alumni, Featured, Nursing, School

Belle Herman Weiss, retired nurse and oldest-known alum of Mount Sinai Phillips School of Nursing (formerly Beth Israel School of Nursing)

At 106 years old, Belle Herman Weiss, RN, is thought to be the oldest living alum from the Beth Israel School of Nursing, now the Mount Sinai Phillips School of Nursing (founded in 1902), and one of the oldest living nurses in New York. Belle, who retired years ago and lives in Westchester County, fondly recalls her time in nursing school, which she began at just 16 years old—during a time when harmful diseases were widespread and difficult to treat.

“I enjoyed all the experiences I had to go through in nursing school,” says Belle, who graduated in 1936. “I loved being with a lot of other young women and having a goal to achieve.”

A good student who loved studying medicine, Belle was fascinated with figuring out patients’ diagnoses, which she compares to being a detective solving medical mysteries. “My favorite subjects were anatomy and physiology. I had a good memory and I was able to remember all the bones and their function. I enjoyed being able to recite the different parts of the body and what they did,” she says.

However, the lack of penicillin and treatments for infectious diseases in the 1930s and 1940s made nursing a challenging—and potentially dangerous—career path. She remembers contracting a skin lesion from tuberculosis at a hospital she worked in, noting she was “very lucky” it did not spread to her chest.

“It was a very difficult time, and [we were] studying at a bad time,” says Belle of being a nursing student. But she says many nurses managed to avoid infections by donning the cloth masks, rubber gloves, and gowns available at the time, and especially, routinely washing their hands. “Luckily, most of us stayed pretty healthy,” she says.

After graduating from the Beth Israel School of Nursing, Belle received a public health degree from New York University, which she says aided her when she later worked for The Willard Parker Hospital in Manhattan, where many patients had polio and were cared for in iron lungs (large horizontal machines that patients would lie in, which stimulated breathing). Medical technology in those days, she explains, was far more rudimentary and cumbersome to work with. For example, intravenous (IV) therapy—a routine therapy administered by nurses today using prepackaged components and fluids—was rarely ordered in the 1930s and 1940s. When it was, nurses had to prepare all the separate components—a glass bottle of saline, a separate rubber stopper and tubing, and a metal needle—and it was quite a process.

How were IVs given in the 1940s and 1950s? 106-year-old nurse Belle Herman Weiss explains:

First you got the IV pole. Then you went into the utility room and you got a sterilized package that contained the container that you were going to put the saline in. Then you got the connection of tubing, and then you got the needle that went with it. Then you got the saline that you had to pour into it. You had to get this glass container connected to the rubber tubing and put a stopper on the tubing so it wouldn’t leak out. Then you filled the container with the saline from a big bottle and hung it on the pole. Then you let the air run out, and then you connected the needle. Before you called a physician to get them to put the IV in, you had to wrap two hot water bottles around the container to warm the fluid to room temperature. That’s how an IV was given.

She says hospitals also lacked antibiotics. In their absence, she says doctors would order “bodily irrigations”—treatments that involved washing out the nose, eyes, ears, throat, and other orifices, in the hope it would wash away disease.

“We used to have a saying, ‘If in doubt, wash it out,’” Belle says, adding that nurses also kept patients healthy by routinely bathing them “head to toe.”

After retiring from nursing at age 70, Belle worked in a doctor’s office as an administrator until she was 92. She put her nursing degree and training to good use over her long career—working at hospitals throughout New York City, Long Island, and Westchester County, as well as on an ambulance, where she helped transport patients with communicable diseases. She says she enjoyed taking care of people, and particularly loved her pediatric patients. One little girl who died from kidney disease stands out to her the most.

“I can still picture her sometimes, walking around her little crib, and reaching out her arms for me to pick her up,” she says. “Those memories stick with me.”

While Belle enjoyed a storied nursing career—in addition to getting married in 1943 and having three children, including a daughter who is an advanced practice nurse in Westchester County—the two-and-a-half years she spent training at the Beth Israel School of Nursing are still fresh in her memory. She remembers the intensive 12-hour work schedules, and still recalls the names of many fellow students and head nurses she trained with. The nursing program was very disciplined, she says, and helped her acquire valuable experience for her nursing career.

“I did get a very good training,” remembers Belle of the Beth Israel School of Nursing.  “We treated the patients with elite nursing care.”

Learn more about the Phillips School of Nursing at Mount Sinai.

Delivering the Future of Vaccines With mRNA Technology

Updated on Jun 15, 2023 | Featured, Research, School, Vaccines

From left to right, Peter Palese, PhD, Horace W. Goldsmith Professor of Medicine; Miriam Merad, MD, PhD, Mount Sinai Professor in Cancer Immunology; Özlem Türeci, MD, Chief Medical Officer of BioNTech; Uğur Şahin, MD, Chief Executive Officer of BioNTech; Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn School of Medicine at Mount Sinai

One of the great tools that helped turn the tide of the COVID-19 pandemic was the use of vaccines, which prevented millions of deaths and hospitalizations in the U.S. and around the world. Key vaccines were those based on messenger RNA (mRNA) technology, which provide information for the molecules that teach the cells in the body to generate proteins used by viruses or cancers, allowing the body’s immune system to recognize and fight off future infections or transformed cancer cells.

The Icahn School of Medicine at Mount Sinai honored the efforts of executives of German biotechnology firm BioNTech, which partnered with Pfizer to develop and make available one of the most widely used COVID-19 vaccines in the country, during its 54th Commencement on Thursday, May 11. Uğur Şahin, MD, Chief Executive Officer of BioNTech, and Özlem Türeci, MD, its Chief Medical Officer, received honorary Doctor of Science degrees.

Research into mRNA technology for vaccines goes back to the 1990s, and has grown in leaps and bounds since, said Dr. Türeci in a guest lecture hosted by the Marc and Jennifer Lipschultz Precision Immunology Institute, held separately from the Commencement.

The COVID-19 pandemic provided an opportunity for the technology to be adapted at a large scale, and the momentum gained and lessons learned was only the starting point to pave the way for greater heights for the development of mRNA vaccines, she said.

In this Q&A, Drs. Şahin and Türeci spoke about what the future of mRNA vaccines could look like.

After two years of COVID-19 vaccines:

  • An estimated 18 million hospitalizations were prevented
  • More than 3 million deaths were avoided
    Source: New York City-based foundation The Commonwealth Fund

Percentage vaccinated in United States by manufacturer:

  • Pfizer/BioNTech: 60%
  • Moderna: 37%
  • Johnson & Johnson: 3%
    Source: Centers for Disease Control and Prevention

What are some active areas of research in which mRNA technology is being worked on?

Dr. Şahin: There are investigational cancer vaccines in which mRNA technology is being used to deliver instructions to generate antibodies or cytokines. This technology can theoretically be used to deliver any bioactive molecule.

Our focus at the moment is the development of cancer vaccines, and one special application of cancer vaccines we’re working on is the so-called “personalized cancer vaccines.” mRNA technology is particularly well suited to deliver a vaccine that consists of mutations of the tumor identified from the patient.

Dr. Türeci presenting to members of the Marc and Jennifer Lipschultz Precision Immunology Institute.

What is it about mRNA technology that makes it so well suited for cancer vaccines?

Dr. Türeci: We have been interested in cancer vaccines all along, and tried different technologies, and mRNA is the delivery technology that comes with its own edge. Its immunogenicity is very versatile and its transience has the potential to lead to a favorable safety profile. These characteristics are the reasons why we chose mRNA to deliver cancer antigens.

Any solid cancer could be appropriate for application. We have ongoing clinical trials in melanoma, head-and-neck cancer, pancreatic cancer, and non-small cell lung cancer.

Beyond cancer vaccines, we believe any bioactive cancer immunotherapy that is based on protein could be delivered by mRNA.

What about non-cancer diseases? Is mRNA technology suitable there?

Dr. Türeci: There are other areas, such as infectious diseases, in which mRNA could have an advantage. As long as you have the right protein structure to stimulate an immune response, you can theoretically also use mRNA here.

There are clinical trials in infectious diseases: COVID-19, for example, but also malaria or shingles.

What are some current limitations of mRNA technology? And how are researchers working to overcome those?

Dr. Türeci: We are very far advanced in the delivery component of the technology, and these advancements have made COVID-19 vaccines, as well as cancer vaccines in clinical testing, feasible. However, if you want to target specific organs, you need specialized, targeted delivery technologies.

For example, if you want to address something in the brain, you need a delivery technology that brings the mRNA into the brain. There may be monogenetic diseases in which the sample protein is deficient in the organ, and so limits how the mRNA can be expressed there.

So the lipid nanoparticle used to contain the COVID-19 vaccine, for example, might not be applicable for any other organs?

Dr. Türeci: This delivery technology was specifically designed and developed to deliver mRNA to the lymphatic system. If the mRNA needs to be delivered to different organs, it required new formulation.

What is a lipid nanoparticle? Read more about it here

When the public first became aware of mRNA technology through COVID-19 vaccines, there was skepticism. Do you envision similar skepticism as new mRNA vaccines roll out, and if so, how can we dispel such skepticism?

Dr. Türeci: Skepticism can only be addressed by transparent communication, through the disclosure of data, and proper education. I think there is a zeitgeist of skepticism. That skepticism isn’t necessarily specific to mRNA technology. But once they start to understand the mechanisms behind the technology, and the rationale of why we’re working on it, we can start to dispel it.

Do you foresee mRNA technology to grow exponentially into the future?

Dr. Şahin: Yes, mRNA vaccines could be really big, but it will happen slowly. It will take a few more years, but we are starting to see really promising candidates using this technology.

Read more about Research at Mount Sinai

Valentin Fuster, MD, PhD, at Commencement: In Pursuit of Progress

Updated on May 31, 2023 | Featured, School

Valentin Fuster, MD, PhD, at Commencement: In Pursuit of Progress

Valentin Fuster, MD, PhD, President of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, giving the Commencement address

Commencements are not only about graduating students being hooded and receiving their degrees, or outstanding individuals being recognized with honorary degrees, but also opportunities for wisdom to be passed down.

At the 54th Commencement of the Icahn School of Medicine at Mount Sinai, held at David Geffen Hall at Lincoln Center on Thursday, May 11, Valentin Fuster, MD, PhD, President of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, had the honor of bestowing wisdom upon a new cohort of physicians and researchers.

“I have the awesome responsibility of providing you with wise and inspiring words, but with the comfort that you might not retain them for more than 24 hours,” began Dr. Fuster with a chuckle. But beyond the humor, Dr. Fuster called on graduates and all present in the hall to reflect on the concept of progress, especially in medicine.

What Does It Mean to Progress?

Society has moved through time, but we can’t take progress for granted, said Dr. Fuster.

At present, and sadly not new in the history of humanity, the concept of progress appears to be challenged, he said. One, by an ongoing abandonment of traditional ethical and moral values, ​​and two, by radical groups threatening one of the most basic principles of human dignity, which is the right to live.

New perspectives of progress can only be advanced by youth with innovative training, and the graduating class at Icahn Mount Sinai represents a group key to that goal, Dr. Fuster noted.

Challenges to Progress

Scientific innovations have forged ahead at a rapid pace, and have created gaps—between digital and cognitive creativity, and between treating disease and preventing it.

In the first category, Dr. Fuster spoke of acceptable uses of recent technologies, such as the artificial intelligence tool ChatGPT, for preparing research manuscripts. However, the definition of acceptable uses should be questioned by the younger generation, he said. “Young people—you—are generally those with the highest exposure to digital technologies, and as such you are uniquely equipped for positive decision-making.”

Furthermore, while advanced technologies have become part of daily lives, clinicians need to realize that the digitization of body data can only be useful to the well-being of the patient when integrated thoroughly with a complete clinical and social history and physical examination—a reality that is being diluted in medical educational systems that are mainly focused on digital technology, Dr. Fuster said.

In the latter category, there remains a gap in thinking about where the line between treatment and prevention should lie. Experts have agreed on the importance of prevention, not just treatment, but there remain questions about when medical practitioners should intervene, Dr. Fuster said, exhorting the young graduates to continue contributing toward prevention efforts.

Contributing to Progress

Being an active participant toward progress can be fulfilling, but the journey will be fraught, said Dr. Fuster. There are three principles that can help during dark moments, he noted.

Resilience is key, as the road to personal fulfillment is long and often marked by frustration. Mentorship is next, as people often spend excessive energy pursuing ambitions before they are ready and tutors can help discover talent. The last is to give back to society, as generosity and empathy are always the basis of happiness.

Finally, Dr. Fuster called on the graduates to live in the moment. “In this special and unique day, please stop your clock and celebrate your achievement,” he said. “And turn the clock back to give thanks to all of those who helped you on this journey, in a sense, to make you ready to engage in progress.”

The honor of delivering the Commencement address is reserved for individuals who have made a big impact in the health and sciences field. Dr. Fuster has a long and illustrious career as a physician and researcher, and in recognition of his achievements, he was conferred an honorary Doctor of Science degree at the 54th Commencement. Here’s a look at his storied career over the decades:

1974-1982

Professorships, including in Medicine and Cardiovascular Diseases, and Pediatrics, at Mayo Medical School, Rochester, Minnesota

1982-1991

Arthur M. and Hilda A. Master Professor of Medicine, Mount Sinai School of Medicine

1991-1994

Mallinckrodt Professor of Medicine, Harvard Medical School, Boston

1994

Dean for Academic Affairs, Mount Sinai School of Medicine

1994-1997

Arthur M. and Hilda A. Master Professor of Medicine, Mount Sinai School of Medicine

1997-present

Richard Gorlin, MD/Heart Research Foundation Professor of Cardiology, Mount Sinai School of Medicine/Icahn School of Medicine at Mount Sinai

2002-present

Director, the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, The Mount Sinai Hospital

2006-2022

Founding Director, Mount Sinai Heart

2007-2009

Scientific Director, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain

2009-present

General Director, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain

2011-present

Physician-in-Chief, The Mount Sinai Hospital

2023-present

President, Mount Sinai Heart

Through work with Mount Sinai Heart, Dr. Fuster has also led initiatives and programs that have had a global impact.

Hypertension management in rural Kenya: Using a multidisciplinary approach to address the challenge of linking and retaining hypertensive individuals to a hypertension-management program, community health workers use a behavioral communication strategy and smartphone-based tools to reduce blood pressure and manage their health.

Sesame Street education project: In 2006, Dr. Fuster joined as an advisor for Sesame Workshop’s Healthy Habits for Life initiative, launched in 2005 to promote healthy lifestyles and diet among young children. In 2012, he collaborated on Sesame Workshop’s Global Health Initiative, and helped create a mini-series Barrio Sésamo: Monstruos Supersanos, or Super Healthy Monsters, which aired on Spain’s co-production of Sesame Street. Segments have since been incorporated into local versions of Sesame Street in Colombia, Germany, Netherlands, United States, and other countries.

Did you know: Dr. Fuster has a Muppet, named Dr. Valentin Ruster, modeled after him? The Muppet doctor is featured in Super Healthy Monsters, and he teaches fellow Muppets about the heart, and even hosts a game show about balanced diets with Cookie Monster as a contestant.

Polypill initiative: Mount Sinai Heart launched a program to combine aspirin, a statin, and an angiotensin-converting enzyme inhibitor into one pill to prevent heart disease. The program was not only launched in the United States, but made available to developing nations, with accompanying studies to determine whether the polypill is effective in reducing cardiovascular disease and improves adherence and accessibility to health care.

Cardiovascular disease prevention in children worldwide project: Dr. Fuster is pursuing a project that helps children acquire a healthy lifestyle and sustain it long-term through early education and intervention, preventing cardiovascular and other diseases later on in life. This project, presently reaching about 50,000 children worldwide, is rooted in the understanding that given greater brain plasticity in early years of life, what is learned and experienced in those ages will be enduring.

A Historic Commencement to Remember

Updated on May 19, 2023 | Alumni, Featured, School

Members of the pioneer classes of Mount Sinai medical school attending the 54th Commencement.

The Icahn School of Medicine at Mount Sinai celebrated its 54th graduating class on Thursday, May 11. A total of 172 degrees were conferred that day, ushering in a new generation of clinicians and researchers. However, the Commencement ceremony also celebrated another historic milestone:

“In attendance today are distinguished alumni who have had long and highly productive careers,” said Kenneth L. Davis, MD, Chief Executive Officer of the Mount Sinai Health System. “They are members of our first few graduating classes, from 1970, ’71, ’72, and my class, 1973. Together, they are celebrating the 50th anniversary of their graduation.”

One distinguished alumni who joined the Icahn Mount Sinai faculty on stage was Jeffery Flier, MD, Class of 1972, who had helped organize events celebrating this milestone. Events in the week leading up to Commencement included the 2023 Alumni Reunion Awards Ceremony Dinner at the New York Academy of Medicine, and a 50th milestone anniversary podcast, which interviewed members of the pioneer class.

“I would frequently tell people, ‘Don’t overthink what your career is going to be,’” Dr. Flier said in the podcast. As advice to recent graduates and future medical students, Dr. Flier noted that many people have many different careers during the course of their medical life, and one can’t predict what their opportunities are going to be. “Look for what you think will give you the greatest pleasure and opportunity that’s facing you right now,” he said.

Throughout the careers of these alumni, they have pushed the frontiers of medicine and science. Hover to read about where some of these outstanding individuals are today:

Ernst Schaefer, MD, class of 1972

Founder and Chief Medical Officer of Boston Heart Diagnostics.

Arthur Frank, MD, PhD, class of 1972

Professor of Public Health and Chair Emeritus of the Department of Environmental and Occupational Health, Drexel University’s School of Public Health, Philadelphia.

Jeffrey Flier, MD, class of 1972

Caroline Shields Walker Professor of Medicine, Harvard Medical School; former Dean of the Faculty of Medicine at Harvard University.

Naomi Luban, MD, class of 1972

Chair of the Institutional Review Board in the Office of Human Subjects Protection at Children’s National Hospital, Washington, D.C.

Learn more about the graduating classes of 1970-1973

Curious how Icahn Mount Sinai has evolved over the years? From its first class to the present, the medical school has pushed itself to higher heights, reinventing itself many times over. Here’s a timeline of Icahn Mount Sinai through the decades.

1963

The New York State Board of Regents granted a charter to The Mount Sinai Hospital to create The Mount Sinai Hospital School of Medicine, permitting the school to grant MD and PhD degrees. A separate but overlapping Board of Trustees for the School was created.

1964

Charter amended to change name to Mount Sinai School of Medicine.

1967

Affiliated with City University of New York, name changed to Mount Sinai School of Medicine of City University of New York. First Faculty Assembly held, with approximately 1,200 faculty members.

1968

First students arrive: a first-year class with 36 students, including four women; a third-year class with 23 students; and 19 students in the Graduate School. Basic Science building on 102nd Street was opened.

1970

The first class of Mount Sinai School of Medicine graduated, with 23 students.

1972

First commencement of graduates who had spent all four years at Mount Sinai School of Medicine.

1973

First classes were held in the Annenberg Building.

1982

Department of Geriatrics and Adult Development created—a first in a U.S. medical school.

1984

Aron Residence Hall opened for medical students.

1987

Humanities and Medicine Program established to attract liberal arts students to careers in medicine

1989

Master of Science Degree in Community Medicine added, later changed to Master in Public Health.

1993

Mount Sinai School of Medicine, for the first time, graduated more women than men; a first in New York State.

1995

The Mount Sinai School of Medicine Consortium for Graduate Medical Education was established.

1996

East Building (now Icahn Medical Institute) opened.

1999

Affiliated with New York University, name changed to Mount Sinai School of Medicine of New York University.

2001

Institute for Medical Education established.

2003

Master of Science in Clinical Research added.

2005

Mount Sinai School of Medicine added new offerings, including Post-Baccalaureate Research Education Program, and Master of Science in Genetic Counseling.

2010

The Middle States Commission granted the School initial accreditation to be a free-standing accredited body and to grant its own degrees. Name changed to Mount Sinai School of Medicine.

1998

First White Coat Ceremony for first-year medical students.

2013

Name changed to Icahn School of Medicine at Mount Sinai in honor of trustee Carl Icahn. Mount Sinai Health System is announced, comprising Icahn Mount Sinai and seven affiliated hospitals. The medical school also announced an affiliation with Rensselaer Polytechnic Institute to collaborate on educational programs, research, and development of new diagnostic tools and treatments.

2015

The Tisch Cancer Institute at Icahn Mount Sinai was named a National Cancer Institute-designated cancer center.

2016

Icahn Mount Sinai and Stony Brook University on Long Island announced a partnership to develop joint graduate and medical educational programs.

2019

Master of Health Administration program added.

Read about the Class of 2023 Commencement

Pin It on Pinterest